Search

Your search keyword '"Raymond Jian"' showing total 3 results
Start Over Author "Raymond Jian" Journal inflammatory bowel diseases
3 results on '"Raymond Jian"'

1. Biodiversity of the Mucosa-Associated Microbiota Is Stable Along the Distal Digestive Tract in Healthy Individuals and Patients With Ibd

Author

Patricia Lepage, Marie-France de la Cochetière, Malène Sutren, Philippe Marteau, Joël Doré, Raymond Jian, Philippe Seksik, Unité de recherche d'Écologie et Physiologie du Système Digestif (UEPSD), Institut National de la Recherche Agronomique (INRA), Biologie et physiopathologie intestinales. Pharmacologie nutritionnelle, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Male, [SDV]Life Sciences [q-bio], Gastroenterology, Inflammatory bowel disease, Feces, 0302 clinical medicine, Crohn Disease, Immunology and Allergy, Aged, 80 and over, 0303 health sciences, education.field_of_study, Middle Aged, Ulcerative colitis, 3. Good health, medicine.anatomical_structure, Female, 030211 gastroenterology & hepatology, Adult, DNA, Bacterial, medicine.medical_specialty, Adolescent, Population, Rectum, Ileum, Biology, DNA, Ribosomal, digestive system, 03 medical and health sciences, Enterobacteriaceae, INTESTINAL MUCOSA, Internal medicine, medicine, Humans, Intestine, Large, Microbiome, Colitis, education, TTGE, Aged, 030304 developmental biology, INFLAMMATORY BOWEL DISEASE, medicine.disease, Case-Control Studies, FECAL MICROBIOTA, Colitis, Ulcerative, BIODIVERSITY, ASSOCIATED-MUCOSA MICROBIOTA
Abstract

International audience; BACKGROUND: The mucosa-associated microbiota, being very close to the inflammatory process associated with inflammatory bowel disease (IBD), may have a pathogenic role. We used a culture-independent method to analyze the mucosa-associated microbiota in IBD patients at various points of the distal digestive tract. METHODS: Thirty-five patients (20 with Crohn's disease, 11 with ulcerative colitis, and 4 controls) underwent colonoscopy. Biopsies (n = 126) were taken from 4 sites: the ileum, right colon, left colon, and rectum. Fecal samples were also obtained from 7 individuals. Temporal temperature gradient gel electrophoresis (TTGE) of 16S rDNA was used to evaluate dominant species diversity. TTGE profiles were compared using software that measures the degree of similarity. RESULTS: In a given individual, the overall similarity percentage between the 4 segments of the distal digestive tract was 94.7 +/- 4.0%, regardless of clinical status. The average similarity of all profiles for a given segment was 59.3 +/- 18.3% in the overall population. Dendrogram analysis showed that TTGE profiles did not cluster with clinical status. Differences were observed between the dominant fecal microbiota and the mucosa-associated microbiota of all 4 sites, with similarity percentages less than 92%. CONCLUSIONS: These results confirm that the dominant species differ between the mucosa-associated and fecal microbiota. They also show that, in a given individual, the microbiota is relatively stable along the distal digestive tract, showing a slight evolution in dominant species diversity from the ileum to the rectum, in both healthy subjects and patients with IBD.

Published
2005
Full Text
View/download PDF

2. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

Author

Jean Yves Mary, Sylvie Rajca, Hélène Pillant, David Laharie, Guillaume Savoye, Yoram Bouhnik, Jean-Charle Grimaud, Harry Sokol, Laurence Picon, Edouard Louis, Michel Veyrac, Martine Devos, Mathurin Flamant, Eric Piver, Gilles Paintaud, Virginie Grondin, Gwenola Vernier-Massouille, Jean-Louis Dupas, Raymond Jian, Matthieu Allez, Philippe Seksik, Jean-Frederic Colombel, Hepato Gastroenterology, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Pole des maladies de l'appareil digestif, gastroentérologie et assistance nutritive, Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépato-Gastro-Entérologie, CHU Bordeaux [Bordeaux]-Hôpital Saint-André, Hepato-Gastroenterologie, CHU Amiens-Picardie, Laboratoire de Météorologie Dynamique (UMR 8539) (LMD), Département des Géosciences - ENS Paris, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École des Ponts ParisTech (ENPC)-École polytechnique (X)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Fédération Médico-Chirurgicale des Maladies de l'Appareil Digestif, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Gastroenterology, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS [2012-2017] (GICC UMR 7292 CNRS), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Virus, pseudo-virus: Morphogénèse et Antigénicité, Université de Tours-EA3856, Biostatistique et épidemiologie clinique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'Hépato-gastroentérologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-École polytechnique (X)-École des Ponts ParisTech (ENPC)-Centre National de la Recherche Scientifique (CNRS)-Département des Géosciences - ENS Paris, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Université de Tours (UT)-EA3856, CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Adult, Male, medicine.medical_specialty, Faecalibacterium prausnitzii, Gut flora, Gastroenterology, Feces, Crohn Disease, Gastrointestinal Agents, Predictive Value of Tests, Recurrence, Internal medicine, medicine, Immunology and Allergy, Humans, Prospective Studies, Prospective cohort study, Crohn's disease, biology, [CHIM.ORGA]Chemical Sciences/Organic chemistry, Microbiota, Antibodies, Monoclonal, biology.organism_classification, medicine.disease, Infliximab, 3. Good health, Discontinuation, Substance Withdrawal Syndrome, Intestines, Immunology, Cohort, Dysbiosis, Female, medicine.drug, Follow-Up Studies
Abstract

International audience; BACKGROUND:: Crohn's disease (CD)-associated dysbiosis could predispose patients to relapse. Gut microbiota composition of patients from the prospective cohort study designed to identify predictive factors of clinical relapse after infliximab discontinuation (STORI Study) was investigated to determine the impact of dysbiosis in CD relapse. METHODS:: Fecal samples from 33 patients with CD in this cohort were collected at baseline, 2 months, 6 months, and at the end of the follow-up period (19 relapsers and 14 nonrelapsers). Healthy volunteers subjects (n = 29) were used as a control group. The fecal microbiota composition was assessed using quantitative PCR, and comparisons between the patient groups were made at different time points using the Wilcoxon test. The analysis of the time-to-relapse was performed according to the baseline median level of each bacterial signal. RESULTS:: Dysbiosis was observed in patients with CD compared with healthy subjects, and it was characterized by low mean counts of Firmicutes (Clostridium coccoides [P = 0.0003], C. leptum [P < 0.0001], and Faecalibacterium prausnitzii [P = 0.003]). Lower rates of Firmicutes were seen in relapsers compared with nonrelapsers. Moreover, a low rate of F. prausnitzii (P = 0.014) and a low rate of Bacteroides (P = 0.030) predicted relapse independently from high C reactive protein level (P = 0.0001). CONCLUSIONS:: In this work, we report that CD-associated dysbiosis, characterized by a decrease in Firmicutes, correlates with the time-to-relapse after infliximab withdrawal. A deficit in some bacterial groups or species, such as F. prausnitzii, may represent a predictive factor for relapse. Restoring normobiosis in CD could be a new goal for optimal CD management.

Published
2014
Full Text
View/download PDF

3. Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis

Author

Philippe Marteau, Wulfran Cacheux, Raymond Jian, Fady Daniel, and Philippe Seksik

Subjects
Adult, Male, medicine.medical_specialty, Aminosalicylic acid, medicine.medical_treatment, Enema, Inflammatory bowel disease, Gastroenterology, 4-Aminosalicylic acid, chemistry.chemical_compound, Drug tolerance, Internal medicine, medicine, Immunology and Allergy, Humans, Mesalamine, business.industry, Pancreatitis, Acute Necrotizing, Drug Tolerance, medicine.disease, Inflammatory Bowel Diseases, Ulcerative colitis, Aminosalicylic Acid, digestive system diseases, surgical procedures, operative, Treatment Outcome, chemistry, Pancreatitis, Acute pancreatitis, Female, business, medicine.drug
Abstract

Derivatives of 5-aminosalicylic acid (5-ASA) used for the treatment of inflammatory bowel disease may induce acute pancreatitis of immunoallergic origin. 4-aminosalicylic acid (4-ASA) differs from its 5-ASA counterpart by the position of the NH2 group and has shown efficacy in ulcerative colitis. The risk of cross intolerance reaction between 5-ASA and 4-ASA has currently never been evaluated. We report three cases of 5-ASA-induced pancreatitis, with no recurrence of pancreatitis during subsequent treatment with 4-ASA enemas. We conclude that 4-ASA enemas are a safe and well-tolerated therapeutic alternative whenever 5-ASA-induced pancreatitis occurs.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results